# Alector, Inc.

**ALEC**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001653087

**E**

**weakest fifth of 370 graded peers in healthcare**

rank 365 of 370; percentile 98.6; sampling error 2.5 points; lower is stronger

A B C D E

**E, the bear**



| Scoreboard | |
|---|---|
| **Profitability** | E<br>percentile 91.0 |
| **Solvency** | D<br>percentile 65.3 |
| **Growth and financing** | D/E<br>percentile 79.7 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $293.2M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway; fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 25, 2026<br>245 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $2.10<br>2026-10-27; market equity $234.5M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 25, 2026*

We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 91.0** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Accruals ratio | 10.8% | (6.6%) | 91.0 | 805 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 65.3** | | | | | | |
| Twelve-month failure probability | 0.90% | 0.07% | 87.8 | 246 | 2026-06-30 | |
| Altman Z double-prime | (9.85) | (0.33) | 61.1 | 751 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 3.83x | 2.94x | 47.2 | 832 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 79.7** | | | | | | |
| Revenue growth, three-year compound | (46.0%) | 10.1% | 94.9 | 413 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (28.1%) | 2.1% | 91.7 | 697 | 2025-12-31 | |
| Net share issuance, one year | 11.4% | 2.5% | 52.4 | 634 | 2026-02-20 | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 4.5 months |
| Fortress balance sheet | cash minus debt is 55,802,000 USD; Altman Z is not used |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 360 | Nektar Therapeutics (NKTR) | 97.3 | E | dilution, short runway |
| 361 | Agenus Inc. (AGEN) | 97.6 | E | dilution, short runway |
| 362 | Vyome Holdings, Inc. (HIND) | 97.8 | E | dilution, late filer, fortress balance sheet |
| 363 | Sintx Technologies, Inc. (SINT) | 98.1 | E | dilution, short runway |
| 364 | Coherus Oncology, Inc. (CHRS) | 98.4 | E | dilution, short runway |
| 365 | Alector, Inc. (ALEC) | 98.6 | E | short runway, fortress balance sheet |
| 366 | Atara Biotherapeutics, Inc. (ATRA) | 98.9 | E | dilution, short runway |
| 367 | HCW Biologics Inc. (HCWB) | 99.2 | E | dilution, short runway, late filer, degenerate inputs, fortress balance sheet |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | |
|---|---|---|---|---|
| 368 | Inovio Pharmaceuticals, Inc. (INO) | 99.5 | E | dilution, short runway, degenerate inputs |
| 369 | PAVmed Inc. (PAVM) | 99.7 | E | dilution, short runway, degenerate inputs |
| 370 | Curis Inc. (CRIS) | 100.0 | E | dilution, short runway, distress |

## What the price implies

*at the 2026-10-27 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (23.6%) | 7.7% | 29 |
| Distance from 52-week high | (22.8%) | (28.6%) | 59 |
| EBIT to enterprise value | (84.5%) | (1.5%) | 8 |
| Free cash flow yield | (78.5%) | (1.0%) | 8 |
| Book value to price | (0.04) | 0.28 | 9 |
| Sales to price | 0.09 | 0.31 | 22 |
| Composite equity issuance, five years | 33.9% | 20.5% | 61 |
| Relative strength against the sector, log excess return | (0.48) | (0.14) | 29 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $59.9M |
| Operating cash flow, four quarters | -$158.2M |
| Months of runway | 4.5 |
| Days since last periodic filing | 83 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $2.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$156.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$142.8M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $168,000 | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 4 | total debt | us-gaap:LongTermDebt | $10.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 5 | book equity | us-gaap:StockholdersEquity | $30.6M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $65.8M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 7 | total debt | us-gaap:LongTermDebt | $10.0M | 2024-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 8 | book equity | us-gaap:StockholdersEquity | $126.8M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $33.0M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 10 | net income | us-gaap:NetIncomeLoss | -$142.9M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$184.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 12 | assets | us-gaap:Assets | $293.2M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 13 | assets | us-gaap:Assets | $468.3M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 14 | current assets | us-gaap:AssetsCurrent | $266.5M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $69.5M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$972.1M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 17 | liabilities | us-gaap:Liabilities | $262.6M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $21.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $100.6M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $97.1M | 2023-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $133.6M | 2022-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $41,000 | 2025-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$229.9M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.3M | 2024-12-31 | 2026-02-25 | 10-K | 26-071593 |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$184.2M | 2023-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.4M | 2023-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$20.3M | 2022-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.1M | 2022-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 29 | assets | us-gaap:Assets | $621.8M | 2023-12-31 | 2025-02-26 | 10-K | 25-027758 |
| 30 | assets | us-gaap:Assets | $787.6M | 2022-12-31 | 2024-02-27 | 10-K | 24-021183 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 110,362,581 | 2026-02-20 | 2026-02-25 | 10-K | 26-071593 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 99,085,888 | 2025-02-21 | 2025-02-26 | 10-K | 25-027758 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.